Newly Diagnosed Glioblastoma – Open
Novocure is sponsoring an FDA approved IDE trial to examine the efficacy and safety of TTF therapy given in combination with temozolomide (Temodar; Merck & Co.) for patients with newly diagnosed glioblastoma brain tumors. This trial is open and recruiting patients at sites throughout the US, Europe and Israel.
For general information about the trial:
To enroll, please contact one of the participating hospitals using the information at this webpage:
For more information about the NovoTTF-100A for the treatment of newly diagnosed glioblastoma multiforme, please visit:
Recurrent Glioblastoma – Completed
Novocure completed a pivotal (phase III) trial of 237 patients with glioblastoma multiforme brain tumors that had recurred after initial treatment. This trial was conducted under an FDA-approved investigational device exemption (IDE) at 28 centers across the US, Europe and Israel. The results from this trial served as the basis for FDA approval of the NovoTTF-100A System for the treatment of patients with recurrent glioblastoma multiforme.
Lung – Planned
Novocure is preparing an IDE submission for a pivotal (phase III) trial of TTF therapy given in combination with chemotherapy for patients with non-small cell lung cancer. Please check back on this website to follow the progress of this clinical program.